INTRODUCTION H
uman gut is home to approximately 100 trillion microorganisms and has about 100 times the number of genes in our genome. 1 In health, gut microbiota exists in ''symbiosis'' and provides the host with a wide range of metabolic capabilities such as breakdown of indigestible plant polysaccharides (PSA), 2 synthesis of vitamins, 3 biotransformation of conjugated bile acids, and degradation of dietary oxalates. 4 Postnatal colonization of the intestine by bacteria educates our immune system and reduces allergic responses to food and environmental antigens. Chronic kidney disease (CKD) is a global public health problem affecting up to 10% of the population. 1 ''Microbiomecentric theory of CKD progression'' proposes that initial adaptive changes in gut microbiome become maladaptive in later stages of CKD, leading to CKD-related complications. 5 Dysbiosis in patients with CKD is being increasingly recognized as a potential therapeutic target, but the science is in its nascent state. In this review, we will discuss the recent advances in the field of gut microbiome and how it could revolutionize management of CKD-related complications.
Gut microbiome in health-symbiosis. Advances in sequencing technology and bioinformatics have revealed the complexity of human microbiome. The human microbial community (microbiota) includes bacteria, Archaea, viruses, phages, fungi, and other microbial Eukarya. Findings from the Human Microbiome Project suggest that each individual's microbiome is unique, each niche is characterized by one or a few signature taxa, and diversity is greatest in the gut with little variation over time. 6, 7 The predominant bacterial groups in the human gastrointestinal tract are bacteroidetes, firmicutes, and actinobacteria. 8 Acquisition of the human microbiota begins at birth, and it undergoes dynamic adaptive changes over time that are influenced by age, sex, race/ethnicity, geography, diet, and host genetics. Findings from the Twins UK study indicate that abundance of many microbial taxa are influenced by host genetics. 8 Thaiss et al 9 showed that intestinal microbiota exhibits diurnal oscillations that are influenced by feeding rhythms, leading to time-specific compositional changes. Metagenomic sequencing of fecal samples demonstrated that bacterial genes involved in energy metabolism and protein synthesis are abundant during the day, whereas those genes related to detoxification become abundant at night. 9 Indeed, gut microbial ecosystem is considered as an organ by itself, whose metabolic capacity exceeds that of liver. Diet has a significant impact on the gut microbiome profile. Muegge et al 10 studied gut microbiome profile in 33 mammalian species and 18 humans and noted that there is clear separation of microbiome by host diet. They reported that the difference in microbiome profile stems from differing metabolic functions required to use the diet. 10 When fecal microbiota of European children was compared to that of children from a rural African village who consume high-fiber diet, it was evident that African children showed a significant enrichment in bacteroidetes and depletion in firmicutes, with a unique abundance of bacteria from the genus Prevotella and Xylanibacter, known to contain a set of bacterial genes for cellulose and xylan hydrolysis. 11 It appears that gut microbiota in African children has coevolved with the PSA-rich diet, allowing them to maximize energy intake from fibers.
Gut microbiome in disease-dysbiosis. Dysbiosis, a term first described by Elie Metchnikoff, 12 refers to an imbalanced intestinal microbial community with quantitative and qualitative changes in the composition and metabolic activities of the gut microbiota. The ''Hygiene hypothesis'' and the ''Old Friends hypothesis'' propose that alterations in gut microbiome induced by hygienic practices may be related to the recent surge in autoimmune diseases and allergic diseases. Indeed, the declining incidence of infectious diseases over the past 50 years appears to be coinciding with the steady rise in the incidence of allergic and autoimmune diseases in developed countries. 13 Dysbiosis of the gut microbiota has been implicated in the pathogenesis of both intestinal and extraintestinal disorders such as allergy and asthma, 14 obesity, 15 diabetes, 16 cardiovascular disease (CVD), and cancer. 17 Emerging evidence indicate that dysbiosis may underlie the obesity epidemic. Chevalier et al 18 show that cold exposure induces marked increase in the ratio of firmicutes to bacteroidetes and almost a complete loss of verrucomicrobia species, including Akkermansia muciniphila, which has been shown to promote energy harvest in a mouse model of obesity. 19 Gut microbiome as a potential source of uremic toxins. In 1965, Einheber and Carter 20 showed that germfree anephric mice survived longer than anephric mice with intact gut microbiome. Yokoyama 21 showed that sterilizing the intestine by antibiotics decreased the fecal and urinary excretion of phenolic and aromatic bacterial metabolites in weanling pigs with normal kidney function. Gut microbiota has been shown to contribute to the generation of several uremic toxins (Table 1) . Using untargeted metabolomic mass spectrometry, Wikoff et al 91 reported that the presence of several protein-bound uremic toxins, such as indoxyl sulfate (IS), hippuric acid, and phenylacetic acid, are dependent on the presence of gut microflora. Aronov et al 92 studied the plasma samples from hemodialysis patients with and without colons and demonstrated that a number of solutes are absent or present only in low concentrations in subjects without colon, suggesting a colonic origin of these molecules. Impaired protein assimilation in uremia leads to influx of undigested proteins into the distal intestine, which favors the proliferation of proteolytic bacteria. 93 Increased protein fermentation results in generation of potentially toxic metabolites such as, ammonia, phenols, amines, indoles, and thiols. 94 Poesen et al 95 studied the stool metabolomics in 20 hemodialysis patients, 20 healthy subjects, and 20 household contacts. Although a clear discrimination was noted between unrelated controls and end-stage renal disease (ESRD) patients, they noted similarity between hemodialysis patients and their household contacts, leading them to conclude that the CKDrelated differences in the human colonic microbial metabolism can be attributed to a large extent to dietary restrictions and to a lesser extent to loss of renal function. However, they did not assess the dietary pattern in this study. Furthermore, in the same study, they noted that the CKD and non-CKD rats that were fed with same diet had significantly different stool metabolomic profile. 95 Prior studies by Vaziri et al 96 have demonstrated extensive change in the structure and function of the gut microbiome in humans and animals with advanced CKD. Individuals with ESRD restrict fruits and vegetable intake, in an attempt to prevent hyperkalemia. These dietary changes have been shown to result in difference in bacterial taxa between ESRD and healthy individuals. Wong et al have described significant Creatinine, Guanidine and Uric acid
Up to 60% of creatinine is excreted by routes other than urine in kidney failure. 25 Colonic bacteria degrade creatinine in the gut. Guanidine is produced by creatinine metabolism by Pseudomonas stutzeri. 26 Intestinal organisms can degrade urate, generating allantoin, allantoic acid, urea and ammonia 27 Guanidine accumulation in CKD 28 increases mortality noticed in animal studies 28 Indoles: indoxyl sulfate (IS) Generated from metabolism of tryptophan, 29 cleared by proximal tubules and increased in CKD. 30, 31 Nephrotoxic via OATmediated uptake by proximal tubule cells, activation of nuclear factor (NF)-Kb and plasminogen activator inhibitor type I [32] [33] [34] Increased expression of genes related to tubulointerstitial fibrosis, 35 aortic and vascular calcification, [36] [37] [38] endothelial cell damage. 39, 40 Lowers erythropoietin production, 41 bone turnover 42 Transport is mediated by organic anion transporter 1 and 3 (OAT1, OAT3). [43] [44] [45] Not effectively removed by HD 46, 47 Indole acetic acid (IAA)
Produced by intestinal bacteria form tryptophan.
Glomerulosclerosis, interstitial fibrosis, 24 oxidative stress 25 Partly removed by hemodialysis [48] [49] [50] Phenols: para (p)-cresol Breakdown of tyrosine and phenylalanine by intestinal bacteria
Renal fibrosis, oxidative stress, increased inflammatory cytokines, 51 all-cause mortality and CVD. 52, 53 Inhibition of endothelial proliferation, increased endothelial permeability 39, 54 Uremic toxin excreted by tubular secretion through specific transporters, [55] [56] [57] accumulates in CKD 58 Phenylacetylglutamine (PAG) Microbe derived, accumulates in uremia. [59] [60] [61] Phenylacetic acid, a precursor of PAG is derived from phenylalanine. 62 Impairs immunoregulation, 63 increases oxidative stress, 64 and osteoblast dysfunction 65 Tubular damage and progression of CKD 62 mediated by phenyl acetic acid
Hippurate
Gut microbial-mammalian co metabolite. 66, 67 Causes anion gap acidosis in CKD 68, 69 Interferes with erythropoiesis and platelet cyclooxygenase activity. 70 Possible glucose intolerance.
Amines polyamines
Play regulatory role in cell function and growth. 71 Polyamine induced cellular downregulation play a role in lack of tissue responses to hormones in uremia 72 Erythropoietin inhibition, anemia of CKD 73 Many polyamines are generated by microbiota from precursor amino acids D-amino acids Bacterial production in the intestinal tract Possible neurotoxicity 74 Plasma levels increase with declining kidney function 75 Trimethylamine-N-oxide (TMAO) Choline is catabolized by intestinal microbiota to trimethylamine gas, which is Associated with higher long-term mortality. [76] [77] [78] Levels are high in CKD. 79 (Continued ) expansion of intestinal bacteria that contain urease, uricase, and indole and p-cresol forming enzymes; and contraction of short chain fatty acid (SCFA) producing bacteria in subjects with ESRD. IS, p-cresol sulfate (PCS), and urea-derived ammonia have deleterious effects, whereas SCFAs are known to have beneficial effects, their changes in intestinal microbial metabolism, therefore, may contribute to uremic toxicity and inflammation. 97 Uremia increases intestinal permeability, both in uremic rats and in patients with CKD, allowing entry of gut derived uremic toxins in to the systemic circulation. Magnusson et al 98, 99 showed increased intestinal permeability to large-molecular-weight polyethylene glycols in the uremic animals and humans with CKD. Ammonia and ammonium hydroxide are generated in abundance from hydrolysis of urea by microbial urease in uremic state. Ammonia generated this way mediates breakdown of the gut epithelial tight junction and contributes to endotoxemia and systemic inflammation. 100, 101 In the presence of CKD, histologic changes, such as reduction of villous height, elongation of the crypts, and infiltration of lamina propria with inflammatory cells, are evident in the intestine. 102 Vaziri et al 103 observed marked reductions in tight junction protein abundance of claudin-1, occludin, and zonula occludens-1 in colonic mucosa in animals with CKD. The disruption of colonic epithelial tight junction could allow translocation of bacteria and endotoxin across the intestinal wall contributing to systemic inflammation in CKD. 104, 105 Thus, disrupted gut barrier function allows translocation of uremic toxins and the impaired excretory function leads to accumulation of these toxins.
Immune modulation. Microbiome immune modulation of host is best exemplified by gut microbial induction of host immune maturation. Various species of gut microbiota have been shown to promote expansion or differentiation of forkhead box protein 3 expressing regulatory T cells (Tregs). Some of these Tregs are implicated in recognition of microbial antigens. 106, 107 Similarly, colonic Tregs are increased in germfree mice with a set of defined benign commensals. 108 Although some gut commensals such as Clostridium species have the potential to promote colonic Tregs, others can control the development and maturation of mucosal and systemic natural killer T cells, 109 and lymphoid structures. 110 Peptidoglycan, an essential component of the bacterial cell wall, is an important molecule that has the potential to modulate peripheral immune function. 111 Gut microbiota is closely involved in regulation of intestinal CD41 cell induction (Fig 1) . Segmented-filamentous bacteria promote induction of Th17 responses, whereas the Bacteroides fragilis and Clostridia species induce IL-10-producing iTregs. A bacterial PSA, produced by [76] [77] [78] Hydrogen sulfide (H2S) Generated by sulfate reducing bacteria in the colon. Inhibits mitochondrial cytochrome-c oxidase. 80 Genotoxic, cytotoxic, and inflammatory. 81 May decrease inflammation and inhibiting renal fibrosis. 82 Can be cardioprotective. 83 Levels reduced in hemodialysis patients 82 
Endotoxin
Binds to lipopolysaccharidebinding protein (LBP), forming a complex that interacts with the MD-2 part of the toll-like receptor 4, anchored by CD14. 84 This stimulates production of inflammatory cytokines 58, 64 Endotoxin translocation causes inflammation in CKD, 76, 85 possible role in progression of atherosclerosis 86, 87 Soluble CD14 associates with progression of CKD, CVD, and mortality [88] [89] [90] Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; HD, hemodialysis; TMAO, trimethylamine-N-oxide.
Bacteroides fragilis, directs the cellular and physical maturation of the developing immune system. 112 Another class of bacterial metabolite, SCFA, are known for their ability to promote T-cell differentiation into both effector and regulatory T cells, depending on immunologic milieu of the host. 113 Since immune regulation is key to transplant survival, it would be most logical to assume that microbiome should influence transplant outcome. Generally, there is loss of diversity with the emergence of a new dominant bacterial population posttransplant. In kidney transplant recipients, an increase in the relative abundance of proteobacteria in the stool samples is observed in the post-transplantation specimens compared with pretransplantation specimens. 114 The microbiome profile post-transplant is strongly influenced by the intensity and type of immunosuppression, renal allograft function, infection, medication use including use of antibiotic and proton pump inhibitors. Gut microbiome is involved in metabolism of drugs and is relevant to dosing of medications in transplant patients. Indeed, fecal Faecalibacterium prausnitzii abundance in the first week of transplantation was positively correlated with future tacrolimus dosing at 1 month. 115 Gut microbiome and progression of CKD. In 1997, Niwa et al proposed the protein metabolite hypothesis, which claims that toxins generated from protein putrefaction by gut microbes are taken up by the organic anion transporters in the renal tubules. This in turn activates cellular pathways leading to cell death and interstitial fibrosis. We proposed that maladaptive dysbiosis contributes to progression of CKD through pathways beyond generation of uremic toxins. 5 Dietary tryptophan is metabolized into indole by tryptophanase in intestinal bacteria such as Escherichia coli. Indole is absorbed into the blood from the intestine and is metabolized to IS in the liver; it is normally excreted in urine (Fig 2) . IS is an aryl hydrocarbon receptor ligand and a transcriptional regulator. A prospective, observational study performed in 268 patients with CKD indicated that IS measured at baseline is a predictor of loss of kidney function. 30 Evidence from animal models suggest that this uremic toxin may damage renal tubular cells. 48 In uremic rats, administration of IS mediates the renal expression of genes related to tubulointerstitial fibrosis, such as transforming growth factor beta-1 (TGF-b1) and tissue inhibitor of metalloproteinases. 35 Osamu et al showed that mouse podocytes exposed to IS exhibited a pro-inflammatory phenotype, decreased expression of podocyte-specific genes, and decreased cell viability. 116 p-Cresol is a colonic fermentation product of the amino acid tyrosine and phenylalanine. Treatment of proximal tubular cells with IS and PCS led to epithelial mesenchymal phenotypic transition in renal tubule with increased expression of transcription factor Snail, fibronectin, and a-smooth muscle actin. Furthermore, in partial nephrectomized mice model, IS or PCS activated the intrarenal renin-angiotensinaldosterone system and interstitial fibrosis and glomerulosclerosis. 117 Trimethylamine-N-oxide (TMAO), a gut microbialdependent metabolite of dietary choline, phosphatidylcholine (lecithin), and L-carnitine, is elevated in CKD. Tang et al found that elevated TMAO concentrations in animal models were associated with corresponding increases in tubulointerstitial fibrosis. Animals with increased TMAO levels also had increased fibrosis and phosphorylation of Smad3, an important regulator of fibrosis. 79 Further studies are needed to see whether TMAO plays a role in progression of CKD.
Gut microbiome in CKD-related complications. Obesity. Obesity is associated with changes in the relative abundance of the 2 dominant bacterial divisions, the bacteroidetes and the firmicutes, as noted in comparisons of the distal gut microbiota of genetically obese mice and their lean littermates, as well as those of obese and lean human volunteers. Through metagenomic and biochemical analysis, Turnbaugh et al 19 found that these changes affect the metabolic potential of the mouse gut microbiota indicating the gut microbiota as an additional contributing factor to the pathophysiology of obesity.
Type II diabetes mellitus. Type II diabetes mellitus patients exhibited an altered intestinal microbiota, characterized by a decrease of bacteroidetes/firmicutes ratio and some functional bacteria (eg, Bifidobacteria) with an increase of various opportunistic pathogens and some endotoxin-producing gram-negative bacteria. [118] [119] [120] It has also been proposed that altered microbiota in obesity modulates intestinal permeability and increases metabolic endotoxin secretion that lead to chronic lowlevel inflammation, 121 ,122 the pathogenesis of insulin resistance, and onset of type II diabetes mellitus. 123, 124 Cardiovascular disease. Emerging evidence support the infectious theory of atherosclerosis. Using 454 pyrosequencing of 16S rRNA genes, Koren et al 125 identified chryseomonas, in all atherosclerotic plaque samples, and veillonella and Streptococcus in atherosclerotic plaques in human subjects. Further study suggested that oral cavity and gut can be sources for atherosclerotic plaque-associated bacteria. A number of products from the microbiome are now known to be associated with CVD. The Bruneck study 126 showed that an elevated endotoxin level is a strong risk factor for the development of atherosclerosis in the general population. We showed that elevated plasma level of sCD14 (the receptor for endotoxin) is associated with CVD and mortality in patients with CKD and hemodialysis patients. 88, 89 Elevated IS level is associated with aortic calcification, increased vascular stiffness, and risk of cardiovascular mortality in patients with CKD. 127 Similarly, elevated plasma PCS level is associated with all-cause mortality and CVD in CKD and ESRD patients. 128 Using metabolomics approach, Hazen's group showed that TMAO, choline, and betaine to be associated with heart disease. 129 In a follow-up study, they showed that elevated TMAO level predicted an increased risk of major adverse cardiovascular events after adjustment for traditional risk factors in 4007 patients undergoing elective coronary angiography. 130 Stubbs et al measured the TMAO levels in 200 patients with CKD, who underwent coronary angiography, and showed that it is a predictor of coronary atherosclerosis and mortality, after adjusting for traditional cardiovascular risk factors. Microbial taxa belonging to the clostridiaceae and peptostreptococcaceae families are positively associated with blood levels of TMAO in humans. 43 Bone mineral metabolism. Uremic toxins are prototypic protein-bound molecules which have a role in the development of CVD and mortality among patients with CKD. 44 Recent research has implicated uremic toxins in the development of bone disease. 45 Elimination of these toxins could be a noble therapeutic intervention in controlling low-turnover bone disease in patients with CKD. 132 Depression. The brain-gut-microbiota axis is a bidirectional signaling between the gut and the brain, which is regulated at neural, endocrine, and immune levels. 133 The subtle alterations in microbiota acquisition or maintenance in early life [134] [135] [136] may act as a vulnerability factor, impacting on endocrine and immune signaling pathways of the brain-gut-microbiota axis, disruption of which may subsequently predispose to stressrelated disorders in adulthood.
Microbiota impacts early in life during critical neurodevelopmental phases 137 and for hypothalamic pituitary adrenal axis. 138 It's an extension of the hygiene hypothesis 139 which has been reconceptualized as the ''Old Friend's hypothesis, '' 140 proposing that low microbial diversity leads to chronic inflammatory disorders including depression. 141, 142 Kwashiorkor. Kwashiorkor and marasmus are 2 forms of severe undernutrition prevalent in regions confronting food insecurity and high burdens of infectious disease. A recent study implicates the gut microbiota as a central factor in the cause of kwashiorkor. 143 To determine the causality of microbiota composition in kwashiorkor, investigators used fecal transplantation in gnotobiotic mice. The mice that received fecal transplants from human donors with kwashiorkor lost a significant amount of weight. Investigators identified potential targets for kwashiorkor that are rooted in the microbiota and also found specific microbes, metabolic pathways, as well as signals that correlated with a lack of sustained improvement.
Application of meta-omics to the study of human gut microbiome. Until recently, studies of the gut microbiome were mostly based on traditional culture methods which allowed cultivation of only a fraction of gut microbiota. 144, 145 Development of advanced nextgeneration sequencing technologies such as 16S rDNA sequence analysis and metagenomics has facilitated the analysis of a much larger number of uncultivated gut microbial microorganisms. [146] [147] [148] [149] Both methods have their own unique advantages; the 16S method is more useful in identifying ''who's there?'' by sequencing of the conserved 16S rDNA gene which is present in all bacteria, 150 whereas the shotgun metagenomic sequencing aims at determining ''what can they do'' by random sequencing of all DNA extracted from the sample. 151 Metagenomics have been successfully applied by both the American Human Microbiome Project 6 and the European project, MetaHIT 120 to facilitate the study of the human intestinal microbiome. Recently, Rossi et al 152 reported the results of their clinical trial in which they evaluated whether synbiotic (prebiotic and probiotic) therapy alters the gut microbiota and reduces serum concentrations of microbiome-generated uremic toxins, IS and PCS, in patients with CKD. Using 16S gene sequencing method, these investigators determined the microbiome profiles of the study participants and found that synbiotics altered the stool microbiome, particularly with enrichment of Bifidobacterium and depletion of ruminococcaceae. Furthermore, the results revealed a significant inverse correlation between changes in the relative abundance of Bifidobacterium spp. and free serum concentrations of both PCS and IS.
Despite its advantages, metagenomics is unable to determine microbial gene expression, and determining the functional activity of the gut microbiome requires application of other methods such as metaproteomics 153 and metabolomics. 154 The 2 methods are very similar but with slightly different focuses; proteomics focuses on study of peptides and proteins, whereas metabolomics aims at identification of small metabolites (,1000 Da). Currently, metabolomics is widely applied to the study of human gut microbiome, particularly in context of intestinal disorders such as colorectal cancer, inflammatory bowel disease, and irritable bowel syndrome. [155] [156] [157] [158] Using metabolite profiling of plasma samples from 1434 Framingham study participants, Rhee et al 84 demonstrated that progression to CKD could be predicted using just 9 metabolites. Another metabolomic study applied nuclear magnetic resonance spectroscopy to determine differences in the plasma metabolic status of stage 3-4 CKD patients and healthy controls. 159 This study revealed the elevation of 14 metabolites in the plasma of uremic patients, which included several previously identified uremic toxins, such as PCS, as well as 2 novel uremic retentions solutes, dimethyl sulfone and 2-hydroxyisobutyric acid. 159 Ideally, to study uremic toxins, both proteomics and metabolomics approaches should be applied as these methods complement each other and each has a unique role in the discovery of uremic retention solutes. 159 Probiotics consist of living bacteria, such as Bifidobacteria species, Lactobacilli, and Streptococci, 160 that can alter gut microbiota and affect the inflammatory state. 161, 162 Treatment with Bacillus pasteurii and Sporlac slowed the progression of kidney disease and prolonged the life span of fifth/ sixth nephrectomized Sprague-Dawley rats. 163 Hemodialysis patients treated with oral Lactobacillus acidophilus showed decreased serum dimethylamine, a potential uremic toxin. In another study, treatment with L. acidophilus ATCC-4356 reduced the atherosclerotic burden in ApoE 2/2 mice. 164 However, the optimal dose of the bacteria needed to achieve engraftment and also whether they will survive in the uremic environment is unclear.
Smart bacteria. Prakash et al 165 reduced blood urea nitrogen in uremic rats by orally administering microencapsulated, genetically engineered live cells that contained living urease-producing E. coli-DH5. Scientists are envisioning the possibility of colonizing our gut with genetically modified ''smart'' bacteria that could potentially treat disease. Advancement in DNA technologies for manipulation of microbial genomes has made it possible to generate tailored bacteria for the treatment of human disorders. These bacteria could be altered to produce a continuous and inexpensive supply of required therapeutic molecules for treatment or scavengers that remove toxic molecules. 166 These molecules may be designed to turn on and off the synthesis of molecules based on the biological need. Researchers have developed bacterial suicide strategies to mitigate possible risks and should permit the safe use of microbes in targeted therapy. 167 Doi and Rabb 168 showed that germfree mice have increased susceptibility to ischemia and reperfusion injury (IRI), which is reversed by colonization with commensal bacteria. This observation suggests that certain gut microbiota products might be protecting against IRI. 169 In an elegant study, Andrade-Oliveira et al 170 showed that treatment with SCFA reduces IRI-induced kidney injury by reducing inflammation, increase in autophagy, a reduction in apoptosis, and an improvement in mitochondrial biogenesis. SCFA are organic fatty acids with 1 to 6 carbons including acetate, propionate, and butyrate. They exert their systemic effects through G protein-coupled receptors and affect a variety of host processes, including energy utilization, host-microbe signaling, and immune modulation. Interestingly, Pluznick et al 171 showed that SCFA may be involved in blood pressure regulation. Olfactory receptor 78 (a receptor for SCFA) expressed in the kidney, where it mediates renin secretion and increases blood pressure, is counteracted by GPR43, which induces vasodilatation. 171 Prebiotics. A prebiotic is a nondigestible food ingredient that has a beneficial effect through its selective stimulation of the growth or activity of one or a limited number of bacteria in the colon. 172, 173 The candidate prebiotics include inulin, fructo-oligosaccharides, galacto-oligosaccharides, soya-oligosaccharides, xylo-oligosaccharides, and pyrodextrins. Prebiotics promote the growth of Bifidobacteria and Lactobacilli species at the expense of other groups of bacteria in the gut, such as Bacteroides species, Clostridia species, and enterobacteria. 174 Preliminary evidence indicates that prebiotic oligofructose-enriched inulin (p-inulin) promotes growth of Bifidobacteria species, mediates weight loss, reduces inflammation, and improves metabolic function. [175] [176] [177] High dietary fiber intake is associated with lower risk of inflammation and reduced mortality in patients with CKD. 178 Meijers et al 179 reported that serum concentrations of p-cresol and IS are reduced by the oral intake of p-inulin in hemodialysis patients. Acarbose is an inhibitor of a-glucosidase enzymes in the intestinal brush-border that blocks the hydrolysis of polysaccharides and oligosaccharides to glucose and other monosaccharides. The delivery of undigested oligosaccharides to the colon promotes growth of saccharolytic bacteria over proteolytic bacteria leading to reduced generation of PCS. 180 Evenepoel et al 180 showed that treatment with acarbose reduces the colonic generation of p-cresol in healthy persons. Synbiotic is the combination of prebiotic and probiotic treatments. Recently completed, synbiotics easing renal failure by improving gut microbiology (SYNERGY) is a randomized, double-blind, placebocontrolled, crossover trial. Patients with CKD, which showed 6 weeks of synbiotic treatment reduced PCS, and not IS. High-fiber (amylose) diet. Results from animal studies show favorable effects of a high-fiber diet in restoring intestinal microbiome, and plasma, cecal, and urine metabolome. 181 Similarly, rats with CKD fed high resistant starch diet had retardation in progression of CKD.
These effects were mediated through partial restoration of intestinal epithelial tight junction, attenuated impairment of Nrf2 activity, lower oxidative stress, inflammation, and fibrosis. 182 Novel therapies. Lubiprostone is a synthetic derivative of prostaglandin, which activates chloride channel in the gut and is used in the treatment of constipation. In a rat model of CKD, treatment with lubiprostone reduced blood urea nitrogen and histologic evidence of fibrosis, which was associated with attenuated inflammation in the kidney and improvement in microbiome profile with proliferation of saccharolytic bacteria. They also noted that microbiome-derived uremic toxins such as IS and TMAO decreased, and the citric acid cycle pathway was activated indicating improved energy metabolism. 183 Trimethylamine (TMA) inhibitor: 3, 3-dimethyl-1-butanol (DMB) is a structural analogue of choline which inhibits microbial TMA formation through inhibition of microbial TMA lyases. 184 DMB decreases plasma TMAO levels in mice placed chronically on cholineor carnitine-supplemented diet. Furthermore, DMB inhibited endogenous macrophage foam cell formation and atherosclerotic lesion development in mice. DMB was detected in some balsamic vinegars, red wines, and in some olive oils and grape seed oils.
CONCLUSIONS AND FUTURE ENDEAVORS
Our understanding of the gut microbiome's physiological functions and pathologic consequences of dysbiosis have led to exploration of various ways of re-establishing symbiosis. Regulation of intestinal immune responses by the presence or absence of certain members of the microbiota opens the exciting possibility of directionally modulating these responses by either changing the composition of the gut bacteria or modifying relevant signaling pathways. Therefore, it will be crucial to elucidate the molecular mechanisms by which commensals influence mucosal responses. Until recently, a reliance on microbiological culture techniques to characterize flora composition limited the studies. Advances in sequencing techniques, bioinformatics, and wide application of metabolomics have greatly expanded our understanding of the role of microbiome in health and disease in general. It is becoming evident that microbiome changes adaptively early in CKD, but later becomes maladaptive and becomes a source for number of uremic toxins. 5 A number of interventions have been proposed and tested in small studies. It is important to define the variation in microbiome profile and associate it with specific metabolome in well-defined studies in patients with CKD and ESRD, with specific attention to diet and other potential confounders. NIDDK is conducting 2 such studies under the auspicious of Hemodialysis Novel Therapies Consortium (ClinicalTrials.gov Identifier: NCT02572882) and CKD Pilot Studies consortium. Future studies should explore the interaction of microbiome with human genome and how the metabolic potential of the microbiome could be harnessed to treat CKD. ACKNOWLEDGMENTS D. S. Raj is supported by National Institutes of Health grants 1R01DK073665-01A1, 1U01DK099924-01, and 1U01DK099914-01.
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